Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5865169 | 0.84 | CYP19A1 (0.35) | CYP19A1CYP11B1CYP11B2NISCHPTGS2 | |
| SCHEMBL5865264 | 0.78 | CYP19A1 (0.35) | CYP19A1CYP11B1CYP11B2NISCHPTGS2 | |
| SCHEMBL5865222 | 0.76 | CYP11B1 (0.42) | CYP19A1CYP11B1CYP11B2NISCHPTGS2 | |
| SCHEMBL5865377 | 0.76 | CYP19A1 (0.33) | CYP19A1CYP11B1CYP11B2NISCHPTGS2 | |
| SCHEMBL5864929 | 0.75 | CYP11B2 (0.37) | CYP19A1CYP11B1CYP11B2NISCHPTGS2 | |
| Fumaric Acid SCHEMBL5865497 | 0.72 | CYP19A1 (0.40) | CYP19A1CYP11B1CYP11B2NISCHPTGS2 | |
| Fumaric Acid SCHEMBL5865493 | 0.72 | CYP19A1 (0.40) | CYP19A1CYP11B1CYP11B2NISCHPTGS2 | |
| SCHEMBL5865423 | 0.67 | CYP19A1 (0.35) | CYP19A1CYP11B1CYP11B2NISCHPTGS2 | |
| SCHEMBL5864777 | 0.65 | CYP11B1 (0.42) | CYP19A1CYP11B1CYP11B2NISCHPTGS2 | |
| SCHEMBL5865430 | 0.65 | CYP11B2 (0.38) | CYP19A1CYP11B1CYP11B2NISCHPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7034044-B2 | Conjugated aromatic compounds with a pyridine substituent | HOFFMANN-LA ROCHE INC. (US) | 2006-04-25 | — | — | US | disclosed |
| US-20060058354-A1 | Conjugated aromatic compounds with a pyridine substituent | ALANINE ALEXANDER | 2006-03-16 | — | — | US | disclosed |
| US-6951875-B2 | Conjugated aromatic compounds with a pyridine substituent | HOFFMANN-LA ROCHE INC. (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1443926-A1 | PYRIDINE DERIVATIVES AS NMDA-RECEPTOR SUBTYPE BLOCKERS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-11 | — | — | EP | disclosed |
| US-20040068118-A1 | Conjugated aromatic compounds with a pyridine substituent | ALANINE ALEXANDER (FR) | 2004-04-08 | — | — | US | disclosed |
| US-20030144525-A1 | Conjugated aromatic compounds with a pyridine substituent | HOFFMANN-LA ROCHE INC. | 2003-07-31 | — | — | US | disclosed |
| WO-2003037333-A1 | PYRIDINE DERIVATIVES AS NMDA-RECEPTOR SUBTYPE BLOCKERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040068118-A1 | Conjugated aromatic compounds with a pyridine substituent | GRIN2B, GRIN1, GRIN2C | CYP19A1 1693/4885CYP11B1 359/4885CYP11B2 317/4885 |
| US-20030144525-A1 | Conjugated aromatic compounds with a pyridine substituent | GRIN2B, GRIN1, GRIN2C | CYP19A1 1693/4885CYP11B1 359/4885CYP11B2 317/4885 |
| US-20060058354-A1 | Conjugated aromatic compounds with a pyridine substituent | GRIN2B, GRIN3A, GRIN2C | CYP19A1 2025/4885CYP11B1 445/4885CYP11B2 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.